Bone metastasis is the most frequent complication in prostate cancer patients and associated outcome remains fatal. Radium223 (Rad223), a bone targeting radioisotope improves overall survival in patients ( months vs. placebo). | An agent-based model of prostate Cancer bone metastasis progression and response to Radium223